Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)
| Market Cap | $810.33M+26.4% |
| Revenue (ttm) | $38.54M-45.6% |
| Net Income | -$62.35M+9.1% |
| EPS | -$0.15+22.0% |
| Shares Out | 445.23M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,685,640 |
| Open | $1.89 |
| Previous Close | $1.87 |
| Day's Range | $1.78 - $1.89 |
| 52-Week Range | $1.10 - $2.68 |
| Beta | 1.08 |
| Analysts | Hold |
| Price Target | $6.00(+229.67%) |
| Earnings Date | Mar 4, 2027 |
About LXRX
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug candidates such as Sotagliflozin, which has successfully concluded Phase III clinical studies for treating both heart failure and type 1 diabetes, and LX9211, currently undergoing Phase II clinical development for neuropathic pain. The firm maintains important strategic collaborations and licensing arrangements with pharmaceutical industry leaders, including Bristol-Myers Squibb Company and Genentech, Inc. Established in 1995, Lexicon Pharmaceuticals, Inc. is based in The Woodlands, Texas.
Lexicon Pharmaceuticals, Inc. Stock Analysis — InsiderScore
Lexicon Pharmaceuticals, Inc. scored higher than 19% of companies evaluated by InsiderBuying, and ranked 57th out of 94 stocks in the biotech sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at Lexicon Pharmaceuticals, Inc. bought $50.0K of stock across 1 purchase in the last 90 days, the largest of them $50.0K.
The average purchase added about 10% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.
Every buyer already held stock, so each purchase is an increase rather than a first position.
This category carries 35% of the Insider Score.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
1 firm rating LXRX in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Mar 4, 2027Earnings report
$LXRX stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in LXRX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by LXRX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
LXRX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
LXRX Revenue by Segment
| Interest and other income | $1.62M | 54.58% |
| Net product and licensing revenue | $1.18M | 39.74% |
| Severance costs | $100.00K | 3.36% |
| Royalties and other revenue | $69.00K | 2.32% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New LXRX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to LXRX from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in LXRX
| VTIVanguard Morningstar Total Stock Market ETF | $13.28M |
| IWMiShares Russell 2000 ETF | $10.95M |
| VXFVanguard Extended Market ETF | $4.55M |
| XPHState Street SPDR S&P Pharmaceuticals ETF | $4.31M |
| IWOiShares Russell 2000 Growth ETF | $4.01M |
| VTWOVanguard Russell 2000 ETF | $2.47M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from LXRX’s recent data — informational, not investment advice
What’s Behind the Score
News check: Q3 revenue beat and positive clinical data on Sotagliflozin cardiovascular effects support optimism, despite Q3 net loss.
Recent Insider Activity
Insider Score Trend Over Time
-1.9 since Nov 10Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| XPH | State Street SPDR S&P Pharmaceuticals ETF | 0.81% |
| BBC | Virtus Biotech Clinical Trials ETF | 0.72% |
| VFLQ | Vanguard U.S. Liquidity Factor ETF | 0.52% |
| QQQS | Invesco NASDAQ Future Gen 200 ETF | 0.47% |
| PILL | Direxion Daily Pharmaceutical & Medical Bull 3X ETF | 0.12% |
| IWC | iShares Micro-Cap ETF | 0.10% |
| VFMO | Vanguard U.S. Momentum Factor ETF | 0.06% |
| TXS | Texas Capital Texas Equity Index ETF | 0.04% |
| VHT | Vanguard Health Care ETF | 0.01% |
| FHLC | Fidelity MSCI Health Care Index ETF | 0.00% |
Weight is the stock’s share of each fund’s holdings.